This company listing is no longer active
Resumen de acción 23Q
VIVO Cannabis Inc. produces and sells cannabis products for the medical and adult-use markets in Canada, Germany, and Australia.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Competidores de VIVO Cannabis Inc.
Historial de precios y rendimiento
Historical stock prices | |
---|---|
Current Share Price | CA$0.014 |
52 Week High | CA$0.05 |
52 Week Low | CA$0.009 |
Beta | 2.12 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | -70.29% |
3 Year Change | -90.53% |
5 Year Change | -98.43% |
Change since IPO | -97.51% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
23Q | DE Pharmaceuticals | Mercado DE | |
---|---|---|---|
7D | 32.7% | -0.4% | -1.3% |
1Y | -70.3% | -19.5% | 4.0% |
Rentabilidad vs. Industria: 23Q underperformed the German Pharmaceuticals industry which returned -10.2% over the past year.
Rentabilidad vs. Mercado: 23Q underperformed the German Market which returned -9.5% over the past year.
Volatilidad de los precios
23Q volatility | |
---|---|
23Q Average Weekly Movement | 41.4% |
Pharmaceuticals Industry Average Movement | 5.7% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.6% |
10% least volatile stocks in DE Market | 2.6% |
Precio estable de las acciones: 23Q's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: Insufficient data to determine 23Q's volatility change over the past year.
Acerca de la empresa
Fundada | Empleados | CEO | Página web |
---|---|---|---|
n/a | 155 | Ray Laflamme | vivocannabis.com |
Resumen de fundamentos de VIVO Cannabis Inc.
Estadísticas fundamentales de 23Q | |
---|---|
Capitalización bursátil | €6.32m |
Beneficios(TTM) | -€32.98m |
Ingresos (TTM) | €17.31m |
0.4x
Ratio precio-ventas (PS)-0.2x
Ratio precio-beneficio (PE)¿Está 23Q sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
Cuenta de resultados (TTM) de 23Q | |
---|---|
Ingresos | CA$25.41m |
Coste de los ingresos | CA$17.30m |
Beneficio bruto | CA$8.11m |
Otros gastos | CA$56.53m |
Beneficios | -CA$48.41m |
Últimos beneficios comunicados
Dec 31, 2022
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) | -0.13 |
Margen bruto | 31.93% |
Margen de beneficio neto | -190.52% |
Ratio deuda/patrimonio | 8.1% |
¿Cómo se ha desempeñado 23Q a largo plazo?
Ver rendimiento histórico y comparativa